Royal Bank of Canada
GEVA

Royal Bank of Canada’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Royal Bank of Canada’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-390
Closed -$38K – 6911
2015
Q1 		$38K Sell
390
-642
-62% -$68K ﹤0.01% 5106
2014
Q4 		$96K Hold
1,032
– – ﹤0.01% 4752
2014
Q3 		$71K Buy
+1,032
New +$73.9K ﹤0.01% 4789
2013
Q4 		– Sell
-435
Closed -$28K – 6410
2013
Q3 		$28K Buy
+435
New +$21.4K ﹤0.01% 5061

Royal Bank of Canada's GEVA Position: Q2 2015 in Review

Royal Bank of Canada sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 390 shares — an estimated $38K sold.

Royal Bank of Canada first reported a position in GEVA in Q3 2013 and held it in 4 quarters. The position peaked at $96K in Q4 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Royal Bank of Canada reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Royal Bank of Canada sold 390 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $38K.
  • Royal Bank of Canada first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013 and held it in 4 quarters.
  • Royal Bank of Canada's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $96K in Q4 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Royal Bank of Canada's 13F filing for Q2 2015, filed 14 Aug 2015.